TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01315821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Description: 5 million units/day for 3 months
Study: NCT02224742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LeucoPatch
Description: LeucoPatch® is prepared by centrifuging one or more 18mL aliquots of the participant's venous blood in the LeucoPatch device and bench-top centrifuge. The centrifugation yields a tough layer of fibrin, with viable white cells and platelets, and this is applied directly to the wound surface using sterile forceps. The wound is then covered with an inert primary dressing, secondary protective dressing and the ulcerated area protected with appropriate off-loading. The patch is prepared and applied each week for up to 20 weeks or until the wound is judged healed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual wound care provided in a multidisciplinary foot care clinic , in accordance with international guidelines.~Components of usual wound care include:~* Formal assessment of ulcer and surrounding skin~* Provision of any necessary off-loading~* Debridement (i) sharp, (ii) other as appropriate (but excluding the use of larvae)~* Appropriate dressing products~* Appropriate antibiotic therapy~* Nutrition and self care~* Optimal glycaemic control~* Revascularisation if deemed clinically necessary~* Continued close observation
Study: NCT03083886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Identify, Coordinated, Enhanced (ICE) Decision Making + PCP led care
Description: Subjects seeking care at a clinic assigned to this arm will receive the ICE care model through referral by their primary care provider. The ICE care model was developed by the Clinical Excellence Research Center at Stanford University based on a review of the peer-reviewed literature for adult subjects with incident neck or back pain less than six weeks in duration who are not using high-dose opioid medications or receiving spine-related long-term disability payments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized Postural Therapy (IPT) + PCP led care
Description: IPT involves the evaluation of a subject's posture to identify postural and alignment deviations and, based on this, a personalized corrective exercise program is prescribed. This method does involve the use of prescription medications, surgery, or manipulation. A treatment course typically lasts eight sessions over eight weeks. In order to allow for the consistent delivery of this arm of the study at multiple study-sites across the country, IPT will be delivered by The Egoscue Method. Egoscue was founded in 1971 and has 25 clinics worldwide.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual PCP led care
Description: Primary care provider will direct patients' care pathway.
Study: NCT01907334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advair Diskus100/50 µg
Description: Advair Diskus 100/50 µg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advair Diskus100/50 µg
Description: Advair Diskus 100/50 µg
Study: NCT02141061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telapristone Acetate, Proellex 12 mg Formulation B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telapristone Acetate, Proellex 12 mg Formulation B
Study: NCT03036930

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HPV Self-Collection
Description: Undergo self-collection of vaginal/cervical samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Nonavalent Vaccine
Description: Given IM
Study: NCT03446677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural Stability Testing
Description: Each subject was instructed to stand in a static bipedal posture on the MatScan® pressure mat and performed 8 balance tasks. Data of center of pressure, antero-posterior sways and medial-lateral sways were collected in each of the conditions. Each task took 30 seconds to be performed. The first 4 tasks were performed with the mat on the hard surface of the floor. These 4 tasks are as follows: standing with eyes open, standing with eyes closed, standing with eyes open looking and actively moving head upward and downward, and standing with eyes closed and the head actively moving upward and downward. The subjects were asked to perform four more tasks while standing on a thick piece of balance foam that was placed on top of the MatScan®. The remaining 4 tasks are as follows: standing with eyes open, standing with eyes closed, standing with eyes open looking and actively moving the head upward and downward, and standing with eyes closed with head actively moving upward and downward.
Study: NCT02427061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Program (Manhood 2.0)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Program (Job Skills Training)
Study: NCT03118622

Intervention type: DEVICE
Intervention: Pentax
Description: Intubation using Pentax video laryngoscope in Pentax group
Study: NCT00345605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Phenylbutyrate
Description: None will be administered during the washout period; 500 mg/kg/day or 10 grams/m2 will be administered during the first one week treatment period in addition to arginine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Phenylbutyrate
Description: None will be administered during the washout period; 500 mg/kg/day or 10 grams/m2 will be administered during the first one week treatment period in addition to arginine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine
Description: Standard therapeutic dose of 500 mg/kg/day or 10 grams/2 will be administered during the washout periods, during the first one week treatment period when receiving arginine plus Buphenyl, 100 mg/kg/day or 2 grams/m2 will be administered, during the second treatment week, when receiving arginine alone, 500 mg/kg/day or 10 grams/m2 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine
Description: Standard therapeutic dose of 500 mg/kg/day or 10 grams/2 will be administered during the washout periods, during the first one week treatment period when receiving arginine plus Buphenyl, 100 mg/kg/day or 2 grams/m2 will be administered, during the second treatment week, when receiving arginine alone, 500 mg/kg/day or 10 grams/m2 will be administered
Study: NCT03467620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Administration of one oral 25-mg capsule of Cannabidiol daily for a duration of 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of one oral placebo capsule daily for a duration of 12 weeks
Study: NCT03538028

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INCAGN02385
Description: INCAGN02385 administered as an intravenous infusion over 30 minutes.
Study: NCT02210780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Administered via subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: An inactive substance containing no medicine administered via subcutaneous injection.
Study: NCT03360929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3759
Description: Strength: 50mg/tablet, 100mg/tablet Dosage and administration: Twice daily administration under fasting state.
Study: NCT03339141

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation position
Description: The investigators assess two different patient's intubation position : supine position and 25° head-up position looking at the intubation score (POGO score).
Study: NCT01907334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flovent Diskus 100 µg
Description: Flovent Diskus 100 µg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine Chloride
Description: Methacholine Chloride in quadrupling concentrations from 0.25 to 64 mg/mL will be given based upon subject's baseline response.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine Chloride
Description: Methacholine Chloride in quadrupling concentrations from 0.25 to 64 mg/mL will be given based upon subject's baseline response.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: Albuterol will be administered at the end of each methacholine challenge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: Albuterol will be administered at the end of each methacholine challenge.
Study: NCT04175366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Decision Making
Description: Shared Decision Making including adapted decision aid.
Study: NCT03284476

Intervention type: OTHER
Intervention: Collection of medical data from ICU patients
Description: Medical data collected on a electronic secured data base
Study: NCT03978923

Intervention type: DEVICE
Intervention: preparation of the implant site with Piezosurgery vs drill
Description: The surgery was always performed by the same operator (M.M.) to reduce the bias of the study. Loco-regional anesthesia was performed with Mepivacaine hydrochloride with 1:100000 adrenaline.~For the preparation of implant sites using traditional methods, the drills were used following manufacturer's protocol by the implant system in use (WINSIX®- BioSAF IN s.r.l, Trezzano Rosa, Trezzano Rosa, Milano - Italy).~For the preparation of sites was used ultrasonic device, (Surgysonic II, Esacrom S.r.l., Imola, Italy). For the final preparation and insertion of implants, 5-6 ultrasound inserts were used in sequence as follows: tip-shape 1st insert (ES012X) and 2nd insert (ES052XG), crown-shape 3rd insert (ES040), 4th insert (ES041), 5 ° insert (ES043) and 6th insert (ES044).~The implant insertion was performed with a maximum torque of 35 Ncm. Finally, the cap screws were positioned, and the flaps were sutured in Vycril® 3.0.

Intervention type: DEVICE
Intervention: preparation of the implant site with Piezosurgery vs drill
Description: The surgery was always performed by the same operator (M.M.) to reduce the bias of the study. Loco-regional anesthesia was performed with Mepivacaine hydrochloride with 1:100000 adrenaline.~For the preparation of implant sites using traditional methods, the drills were used following manufacturer's protocol by the implant system in use (WINSIX®- BioSAF IN s.r.l, Trezzano Rosa, Trezzano Rosa, Milano - Italy).~For the preparation of sites was used ultrasonic device, (Surgysonic II, Esacrom S.r.l., Imola, Italy). For the final preparation and insertion of implants, 5-6 ultrasound inserts were used in sequence as follows: tip-shape 1st insert (ES012X) and 2nd insert (ES052XG), crown-shape 3rd insert (ES040), 4th insert (ES041), 5 ° insert (ES043) and 6th insert (ES044).~The implant insertion was performed with a maximum torque of 35 Ncm. Finally, the cap screws were positioned, and the flaps were sutured in Vycril® 3.0.
Study: NCT02622737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional training
Description: Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a functional training and 5 minutes of respiratory exercises.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stationary bike
Description: Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a Stationary Bike exercise and 5 minutes of respiratory exercises.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a Virtual Reality exercise (performed by Xbox360 with KinectTM sensor) and 5 minutes of respiratory exercises.
Study: NCT00056667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation response and cognitive behavioral therapy
Description: The cognitive behavioral therapy program wwill incorporate relaxation training, a modified version of the RA treatment program developed by Bradley et al (1987) and shown to be effective. The cognitive behavioral techniques include problem solving, relabeling, enhanced awareness of pain behaviors, and attention refocusing. The RR component includes instruction in diaphragmatic breathing along with progressive skeletal muscle relaxation. The intervention will be modified from the original program in that neither biofeedback training nor participation of family members will be included. Consequently, the number of weekly group sessions will be reduced from 14 to 12. Homework will be given at the end of each session, to be completed and brought in for review to the next session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation response
Description: The relaxation response (RR) consists of a set of integrated physiological changes elicited when a participant engages in the repetitive mental action of focusing on a word, phrase, or image, while passively ignoring distracting thoughts. These changes include decreased oxygen consumption, heart rate, arterial blood pressure, respiratory rate, and arterial blood lactate, along with slight increases in skeletal muscle blood flow. The long-term physiologic changes of participants eliciting the relaxation response are consistent with reduced norepinephrine end organ responsivity. These latter changes provide a plausible psychophysiological mechanism for longer-term actions of the RR.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: RA education
Description: RA education programs have been widely used to supplement routine medical care. They have been found to be of modest benefit, particularly in terms of knowledge about the condition and its treatment. The long-term effects on pain and level of function are less. When used as an attention control, such educational programs have been found to be as credible and as well attended as the active experimental treatment (Professor Francis Keefe, Personal Communication). In this study, patients randomized to the control condition will receive 8 weekly sessions of RA education, in groups of 6-10 patients each, using portions of the Arthritis Self-Management Program and incorporating printed and videotaped materials available from the Arthritis Foundation.
Study: NCT02957318

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FiberBind
Description: Potato pulp consisting of 68% fiber (5.5 soluble, 76.7% insoluble and 17.8% resistant starch), 9.7% water, 0.3% fat, 7.2% protein and 14% carbohydrates (starch).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RG-I fiber
Description: Soluble fiber extracted from potato pulp consisting of 95% fiber and 5% water.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Low-fiber control
Study: NCT03649477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.2 mg intranasal carbetocin
Description: three times per day with meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9.6 mg intranasal carbetocin
Description: three times per day with meals

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: three times per day with meals
Study: NCT05070052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: 9 sessions of CBT weekly treatment in group setting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based cognitive therapy
Description: 9 sessions of MBCT weekly treatment in group setting
Study: NCT02005419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment, and also receive placebo (Arm I)/ metformin (Arm II) on days 1-28. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Patients receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment, and also receive placebo (Arm I)/ metformin (Arm II) on days 1-28. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
Study: NCT03535896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HSR
Description: Participants will complete a heel raise standing with the forefoot on a step. The toes are maximally dorsiflexed by placing a towel underneath them. The heel raise is performed with a raise to maximal plantar flexion and to maximal dorsi flexion.~The exercise is performed with a load as heavy as possible but no heavier than 8RM and for as many sets as possible every other day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Description: Participants receive an ultrasound-guided corticosteroid injection between 5 and 8 days after baseline. A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid (Lederspan, Meda) + 1 ml Lidocain 10 mg7ml (Xylocain, AstraZeneca). The skin is cleansed with Chlorhexidine alcohol 0.5 % (Medic). The needle is inserted with a medial approach under ultrasound-guidance aligned to the long axis of the ultrasound transducer. The injection is placed anterior to the plantar fascia insertion on the calcaneal bone in the region of maximal fascia thickness.
Study: NCT00934050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELND005 (scyllo-inositol)
Description: Prior to 15Dec2009: ELND005 2000 mg PO BID for 48 weeks~After 15Dec2009: ELND005 250 mg PO BID for 48 weeks
Study: NCT01294787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol and glycopyrronium bromide (QVA149)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Study: NCT03339141

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intubation position
Description: The investigators assess two different patient's intubation position : supine position and 25° head-up position looking at the intubation score (POGO score).
Study: NCT02209285

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Management Program for Older Adults with Multimorbidity
Description: Individuals in the intervention group will receive a six-month community intervention consisting of three components: (1) intensive case management and community navigation; (2) a maximum of two in-home visits by the care coordinator, two in-home visits by a Registered Nurse, and three in-home visits by the Occupational therapist or Physiotherapist, and six visits by a Personal Support Worker over 6 months in addition to usual home care services; and (3) monthly interprofessional team case conferences to develop an evidence-based, patient-centred community reintegration plan.
Study: NCT01521533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-A12
Description: Pilot Group (NOX A12 single agent, and combined with VD):~* 3 cohorts of 3 patients will receive treatment with NOX A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX A12 and VD will start. The combination of NOX A12 and VD will follow a dose titration design beginning at 1 mg/kg NOX A12 (cycle 1) proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX A12 in combination with VD. This is followed by consolidation in cycles 4-8 when NOX-A12 will be kept at the highest individually titrated dose.~Expansion Group (NOX A12 in combination with VD):~* Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group.
Study: NCT03267381

Intervention type: OTHER
Intervention: Blood draw (before surgery)
Description: Blood will be drawn before surgery

Intervention type: OTHER
Intervention: Blood draw (before surgery)
Description: Blood will be drawn before surgery

Intervention type: OTHER
Intervention: Blood draw (before surgery)
Description: Blood will be drawn before surgery

Intervention type: OTHER
Intervention: Blood draw (every 3 months)
Description: Blood will be drawn every 3 months

Intervention type: OTHER
Intervention: Blood draw (every 3 months)
Description: Blood will be drawn every 3 months

Intervention type: OTHER
Intervention: Blood draw (at diagnosis)
Description: Blood will be drawn at time of diagnosis
Study: NCT04457674

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy for insomnia (CBTi)
Description: CBTi consists of six weekly sessions of individual therapy with a trained therapist, delivered via telemedicine.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleep Hygiene Education (SHE)
Description: SHE participants receive six weekly sessions of individual therapy with a trained therapist, delivered via telemedicine.
Study: NCT03045250

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Corneal confocal microscopy
Description: Confocal miscroscopy will be used to assess corneal nerve changes due to hyperglycemia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal confocal microscopy
Description: Confocal miscroscopy will be used to assess corneal nerve changes due to hyperglycemia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsy
Description: Skin biopsy will be used to assess the appearance of nerve fibers in subjects with type 1 diabetes.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Nerve conduction study
Description: Nerve conduction studies will be use to assess for neuropathy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve conduction study
Description: Nerve conduction studies will be use to assess for neuropathy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood draw
Description: Subjects will undergo a one time blood draw for biomarkers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: Subjects will undergo a one time blood draw for biomarkers.